In fact this hypothesis seems fairly coherent with the increased levels of TGF-β observed in control tumors when compared with tumors originated from DABK-treated cells, as it is known that tumor cells as well as regulatory T cells secrete TGF-β to inhibit immune response [56]. This evidence concerns the gene TGFB1 and neoplasm.